Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $132 | $70,570 | $75 | $72 |
Gross Profit | -188 | 70,570 | 75 | 72 |
EBITDA | -114,087 | -33,929 | -100,108 | -86,209 |
EBIT | -113,747 | -34,039 | -100,221 | -86,326 |
Net Income | -120,355 | -34,599 | -100,735 | -86,912 |
Net Change In Cash | 132 | 70,570 | 75 | 72 |
Free Cash Flow | -23,994 | -84,738 | -75,415 | -92,739 |
Cash | 212,382 | 169,647 | 117,324 | 116,215 |
Basic Shares | 84,803 | 81,784 | 81,593 | 81,344 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $70,849 | $302 | $314 | $1,772 |
Gross Profit | 69,689 | 302 | 314 | 1,772 |
EBITDA | -336,493 | -265,663 | -235,365 | -129,133 |
EBIT | -337,653 | -266,903 | -235,887 | -129,388 |
Net Income | -342,601 | -269,949 | -237,734 | -129,874 |
Net Change In Cash | 70,849 | 302 | 314 | 1,772 |
Cost of Revenue | 113,280 | |||
Free Cash Flow | -276,886 | -232,830 | -185,068 | -94,635 |
Cash | 212,382 | 99,594 | 102,827 | 155,579 |
Basic Shares | 84,803 | 67,886 | 44,755 | 32,087 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$1.08 |
2025-09-30 | -$0.34 |
2025-06-30 | -$1 |
2025-03-31 | -$0.86 |
